First-of-its-kind data shows Novartis’ iscalimab extends survival of transplanted kidneys
June 6, 2019Research and Development Novartis, iscalimab, kidney transplant, pharma, transplant
In a first-of-its-kind reveal, Novartis has presented histology data for iscalimab (CFZ533) at the American Transplant Congress (ATC) which indicates …
Takeda’s Ninlaro fails to meet one of two primary endpoints in Phase 3 trial
June 6, 2019Research and Development TOURMALINE-AL1, Takeda, pharma, phase 3, trial Ninlaro
Takeda has decided to discontinue its Phase 3 study of Ninlaro (ixazomib) after the drug in combination with dexamethasone, failed …
Pfizer supressed research suggesting arthritis drug Enbrel reduced risk of Alzheimer’s by 64%
June 6, 2019Research and Development Alzheimer's, Drug therapy, Pfizer, dementia, pharma
Pfizer supressed data suggesting that their drug Enbrel reduced the risk of patients developing Alzheimer’s disease by 64%. In 2015, …
AstraZeneca’s Calquence shows strength in most common adult leukaemia
June 6, 2019Research and Development AstraZeneca, Calquence, chronic lymphocytic leukaemia, pharma
AstraZeneca has unveiled new Phase 3 data for Calquence (acalabrutinib) in treatment-naïve chronic lymphocytic leukaemia, showing that the drug met …
Donald Trump causes confusion as to whether NHS will be ‘on the table’ in trade deal talks
June 6, 2019Business Services, Medical Communications Donald Trump, NHS, UK, US, healthcare, pharma
President Donald Trump has caused confusion as to whether or not the NHS will ‘be on the table’ in post-Brexit …
FDA approves new indication for MSD’s Zerbaxa
June 5, 2019Research and Development Merck, Zerbaxa, bacterial infection, pharma
The FDA has approved US firm Merck’s Zerbaxa (ceftolozane and tazobactam) for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial …
AbbVie’s Venclyxto combo outclasses chemo in treatment-naive chronic lymphocytic leukaemia
June 5, 2019Research and Development ASCO 2019, AbbVie, Venclyxto, pharma
AbbVie was one of many companies to present new data at this year’s American Society of Clinical Oncology (ASCO) Annual …
Cases of sexually transmitted infections on the rise in England, data shows
June 5, 2019Research and Development HIV, STDs, STIs, pharma PrEP, public health
Cases of sexually transmitted infections (STIs) are on the rise, according to new data from Public Health England. There were …
Parents of children with cystic fibrosis start Orkambi buyers club
June 5, 2019Research and Development NHS, Orkambi, Vertex, cystic fibrosis
Parents of children with cystic fibrosis have started an Orkambi buyers’ club to import generic versions of Vertex’s drug from …
Eli Lilly’s Emgality approved in the US for episodic cluster headache
June 5, 2019Research and Development, Sales and Marketing Eli Lilly, Emgality, episodic cluster headache, migraine, pharma
Eli Lilly’s Emgality (galcanezumab-gnlm) self-administered injection solution has secured approval in the US for the treatment of episodic cluster headache, …
NeoImmuneTech names experienced pharma exec Dr Samuel Zhang as company’s new Chief Business Officer
June 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Maryland-based biotech NeoImmuneTech has named Dr Samuel Zhang as the company’s new Chief Business Officer (CBO). Dr Zhang brings to …
Former FDA Commissioner returns to venture capital firm
June 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Scott Gottlieb, appointment, pharma
Dr Scott Gottlieb, former Commissioner for the FDA, has returned to his venture capital background with the announcement that he …
Darzalex combo makes strong Phase 3 showing in multiple myeloma
June 4, 2019Manufacturing and Production, Research and Development ASCO 2019, Cancer, Janssen, darzalex, multiple myeloma, pharma
Janssen joined its contemporaries at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in the release …
Janssen’s Imbruvica shows superiority in Phase 3 trials
June 4, 2019Manufacturing and Production Janssen, imbruvia, leukaemia, pharma, phase 3, trial
Phase 3 data from ASCO 2019 has shown Janssen’s leukaemia drug Imbruvica (ibrutinib) had significant benefits over ofatumumab. In the …
Amgen’s novel KRAS inhibitor monotherapy shows promise at Phase 1 in advanced solid tumours
June 4, 2019Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, KRAS
Amgen has unveiled the first clinical data for its investigational KRAS inhibitor AMG 510, the first such therapy to reach …
EMA approves Bluebird Bio’s gene therapy Zynteglo
June 4, 2019Manufacturing and Production Bluebird Bio, European comission, gene therapy, health, pharma
The European Commission has granted a conditional marketing authorisation to bluebird bio’s gene therapy Zynteglo. The Massachusetts-based firm’s one time …
Walmart join MediLedger medical supply chain blockchain network
June 3, 2019Manufacturing and Production MediLedger, blockchain, medical supply chain, pharma
Walmart has joined the MediLedger network – a network of pharma firms who use a permissioned blockchain to manage the …
Working Life: Monika Pocinkova, Vice President, HR Speciality Care, Ipsen UK & Ireland
June 3, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Working Life, feature, pharma
Ipsen’s Vice President of HR Speciality Care discusses the path she has taken throughout her career, the cultural differences she …
Janssen’s Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer
June 3, 2019Research and Development, Sales and Marketing ASCO 2019, Cancer, Erleada, Janssen, prostate cancer
Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new …
Isatuximab improves on standard of care treatments for multiple myeloma
June 3, 2019Sales and Marketing Cancer, Immunogen, Sanofi, isatuximab, multiple myeloma, pharma
Sanofi and ImmunoGen’s isatuximab combination therapy prolonged progression free survival by five months compared to standard of care treatments in …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
